CN101125852A - 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 - Google Patents
5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 Download PDFInfo
- Publication number
- CN101125852A CN101125852A CNA2007101488135A CN200710148813A CN101125852A CN 101125852 A CN101125852 A CN 101125852A CN A2007101488135 A CNA2007101488135 A CN A2007101488135A CN 200710148813 A CN200710148813 A CN 200710148813A CN 101125852 A CN101125852 A CN 101125852A
- Authority
- CN
- China
- Prior art keywords
- sodium salt
- thiazolidine
- pyridyl
- benzyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 159000000000 sodium salts Chemical class 0.000 title claims abstract description 77
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical class C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 33
- 239000012453 solvate Substances 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 16
- 238000010521 absorption reaction Methods 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 13
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 11
- 239000003472 antidiabetic agent Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 238000001228 spectrum Methods 0.000 claims description 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 238000001237 Raman spectrum Methods 0.000 claims description 4
- 238000002329 infrared spectrum Methods 0.000 claims description 4
- 231100000956 nontoxicity Toxicity 0.000 claims description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- WOKWRTYYPDBXRY-UHFFFAOYSA-N sodium;1,3-thiazolidine-2,4-dione Chemical compound [Na].O=C1CSC(=O)N1 WOKWRTYYPDBXRY-UHFFFAOYSA-N 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 125000005594 diketone group Chemical group 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000004283 biguanides Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012943 hotmelt Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- -1 solid dosage Chemical class 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- PMUIBVMKQVKHBE-UHFFFAOYSA-N [S].NC(N)=O Chemical compound [S].NC(N)=O PMUIBVMKQVKHBE-UHFFFAOYSA-N 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 208000004104 gestational diabetes Diseases 0.000 description 2
- 206010061989 glomerulosclerosis Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010067671 Disease complication Diseases 0.000 description 1
- 238000005079 FT-Raman Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920004449 Halon® Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 229920004459 Kel-F® PCTFE Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 241000220304 Prunus dulcis Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- UUAGAQFQZIEFAH-UHFFFAOYSA-N chlorotrifluoroethylene Chemical compound FC(F)=C(F)Cl UUAGAQFQZIEFAH-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005388 cross polarization Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940095107 e.s.p. Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000035879 hyperinsulinaemia Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000000449 magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000010128 melt processing Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
化合物5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮钠盐,或其可药用的溶剂化物,其特征在于钠盐是非吸湿的或略微吸湿的;包含所述化合物的药物组合物和所述化合物在药物中的应用。
Description
本申请是申请日为2001年9月28日、申请号为01816562.1(PCT国际申请号:PCT/GB01/04334)、题目为:5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐的分案申请。
本发明涉及新药物、制备该药物的方法和该药物在药品中的应用。
公开号为0,306,228的欧洲专利申请涉及某些公开为具有低血糖症(hypoglycaemic)和促使血清脂质减少的(hypolipidaemic)活性的噻唑烷-2,4-二酮衍生物。EP 0,306,228的实施例30的化合物是5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮(下文也称为“化合物(I)”)。
公开号为WO 94/05659的国际专利申请披露了EP 0,306,228的化合物的某些盐。WO 94/05659的优选盐是马来酸盐。
现已经发现,化合物(I)形成新钠盐(下文也称为“钠盐”)。
新钠盐是稳定的、具有高熔点的结晶物质,因此适用于大量制备和处理。钠盐能经受大规模的药物加工,特别是在需要或产生热的生产方法中,例如研磨、流化床干燥、喷雾干燥、通过高压杀菌(autoclaving)热熔加工和杀菌。可以通过特别适用于大规模制备的高效、经济和可再现的方法制备新盐。另外,新钠盐是非吸湿的且呈现出良好的固态稳定性,特别是在潮湿条件下时。
该新的钠盐也具有有用的药物性能且特别是其可用于治疗和/或预防糖尿病、与糖尿病相关的疾病及其某些特定的并发症。
因此,本发明提供了5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮,钠盐,尤其是非吸湿性的钠盐或其溶剂化物。
在一个优选的方面,钠盐提供了基本上如图1的红外光谱。
在一个优选的方面,钠盐提供了基本上如图2的拉曼光谱。
在一个优选的方面,钠盐提供了基本上如表1或图3的X-射线粉末衍射图谱(XRPD)。
在一个优选的方面,钠盐提供了基本上如图4的固态13C NMR波谱。
在一个优选的方面,本发明提供了5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮,钠盐,或其溶剂化物,其特征在于它提供:
(i)基本上如图1的红外光谱;
(ii)基本上如图2的拉曼光谱;
(iii)基本上如表1或图3的X-射线粉末衍射图谱(XRPD);和
(iv)基本上如图4的固态13C NMR波谱。
钠盐的合适熔点范围为245~250℃,如246~249℃,例如246℃或249℃。
本发明包括以纯净形式离析或与其它物质掺混的钠盐或其溶剂化物。因此,在一个方面,提供了离析形式的钠盐或其溶剂化物。
在另一个方面,提供了纯净形式的钠盐或其溶剂化物。
在再一个方面,提供了结晶形式的钠盐或其溶剂化物。
并且,本发明提供了固体可药用盐形式如固体剂型,特别是适用于口服的钠盐或其溶剂化物。
并且,本发明还提供了可药用形式、特别是松散形式(bulk form)的钠盐或其溶剂化物,所述形式特别能够进行药物加工,特别是在需要或产生热量的生产方法,例如研磨;例如加热干燥特别是流化床干燥或喷雾干燥;例如热熔加工;例如加热灭菌如高压灭菌。
而且,本发明提供了钠盐或其溶剂化物,其呈可药用形式、特别是松散形式以及特别呈已经被需要或产生热量的生产方法处理过的形式,例如研磨过的形式;例如热干燥的形式,特别是流化床干燥形式或喷雾干燥的形式;例如呈热熔加工过的形式;例如呈通过如高压灭菌法进行加热灭菌的形式。
如上文所述,本发明的钠盐是非吸湿的。本发明还包括钠盐的非吸湿的或略微吸湿的可药用的溶剂化物,包括水合物。
本发明还提供了制备钠盐或其溶剂化物的方法,其特征在于5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮(化合物(I))或其盐,优选分散或溶解在合适的溶剂中,与钠离子源进行反应,然后,如果需要,制备所得的钠盐的溶剂化物;以及回收钠盐或其溶剂化物。
合适的反应溶剂是链烷醇如丙-2-醇,或醚如四氢呋喃,烃如甲苯,酮如丙酮,酯如乙酸乙酯,腈如乙腈或卤化烃如二氯甲烷,或水;或其混合物。
方便的钠离子源是氢氧化钠。氢氧化钠优选以固体或溶液例如在水或低级醇如甲醇、乙醇或丙-2-醇,或溶剂的混合物中的形式加入。
化合物(I)的浓度范围优选是2~25%重量/体积,更优选是5~20%。氢氧化钠溶液的浓度范围优选是2~111%重量/体积。
反应通常在环境温度或高温如50-60℃或在溶剂的回流温度下进行,尽管可以使用提供所需产物的任何适宜温度。
根据常规方法制备钠盐的溶剂化物如水合物。
所需化合物的回收通常包括从合适的溶剂、合适地是反应溶剂中结晶,通常在冷却的帮助下进行。例如,可以从醇如丙-2-醇,醚如四氢呋喃,或水,或其混合物中将钠盐进行结晶。通过蒸发一些或所有溶剂或通过在高温下结晶随后进行受控的冷却,任选分阶段进行而改进盐的收率。可以通过小心控制沉淀温度和放入晶种(seeding)来改进产品形式的再现性。
也可以通过用钠盐或其溶剂化物的晶体作为晶种来开始结晶,但这并非是必要的。
根据已知的方法如EP 0,306,228和WO 94/05659披露的方法来制备化合物(I)。将EP 0,306,228和WO 94/05659的公开内容引入本发明作为参考。
氢氧化钠是市场上可买到的化合物。
用于本发明中的术语“T起始”通常通过差示扫描量热法测定且具有本领域通常理解的含义,如在″Pharmaceutical Thermal Analysis,Techniques andApplications″,Ford and Timmins,1989中表示为“相当于预跃迁基线和跃迁的外推前边的交叉点的温度”。
用于本发明中的术语“预防与糖尿病相关的疾病”包括治疗疾病如胰岛素耐受(insulin resistance)、葡萄糖耐量降低(impaired glucose tolerance)、血胰岛素过多症(hyperinsulinaemia)和妊娠糖尿病(gestational diabetes)。
用于本发明中的有关吸湿性(hygroscopicity)的术语根据已知的标准使用,如在J C Callahan等人,Drug Development and Industrial Pharmacy,1982,8(3),355-69中所述,根据在温度和湿度的受控条件(25℃和75%相对湿度)下根据测试化合物的重量增加的%将吸湿性进行分类,其中已经使测试化合物达到大致恒定的重量:使用下列分类:
%重量增加 分类
<2% 非吸湿的
2-10% 略微吸湿的
10-20% 中度吸湿的
>20% 非常吸湿的
为避免怀疑,用于本发明中的术语“非吸湿的”、“略微吸湿的”、“中度吸湿的”、“非常吸湿的”将具有上述标准所定义的含义。
而且,术语“略微吸湿的”可以具体指根据上述标准化合物所呈现的重量增加的%是2-9%,2-8%,2-7%,2-6%,2-5%,2-4%和2-3%中的任一个。
用于本发明中的术语“可药用的”包括人用和兽医用的化合物、组合物和组分:例如“可药用的盐”包括兽医学上可接受的盐。
“糖尿病”优选指II型糖尿病。
与糖尿病相关的疾病包括高血糖症(hyperglycaemia)、胰岛素耐受(insulin resistance)和肥胖症。与糖尿病相关的其它疾病包括高血压、心血管疾病,特别是动脉粥样硬化症,某些进食障碍疾患(eating disorder),特别是调节患者的食欲和食物摄入,上述患者患有与饮食不足(under-eating)相关的失调如神经性食欲缺乏,和与饮食过量相关的失调如肥胖症和厌食易饿(anorexia bulimia)相关的失调。与糖尿病相关的其它疾病包括多囊卵巢综合征和类固醇诱发的胰岛素耐受(steroid induced insulin resistance)。
包括在本发明中的与糖尿病相关的疾病并发症包括肾病,尤其是与II型糖尿病的进展相关的肾病包括糖尿病性肾病(diabetic nephropathy)、血管球性肾炎、肾小球硬化症(glomerular sclerosis)、肾病综合征(nephroticsyndrome),高血压肾硬化(hypertensive nephrosclerosis)和晚期肾病(end stagerenal disease)。
如上文所述,本发明的化合物具有有用的治疗性能:本发明因此提供了用作活性治疗物质的其钠盐。
更具体的是,本发明提供了用于治疗和/或预防糖尿病、与糖尿病相关的疾病及其某些特定的并发症的钠盐。
钠盐可以直接给药,或优选作为还包含可药用的载体的药物组合物的形式给药。适用于配制钠盐的方法通常披露在上述公开化合物(I)的公开文件中。
因此,本发明也提供了包含钠盐及其可药用的载体的药物组合物。
钠盐通常以单剂型给药。
可以通过任何合适的路径但通常通过口服或胃肠外路径给药活性化合物。对于这类用途来说,通常以与药物载体、稀释剂和/或赋形剂联合使用的药物组合物的形式来使用化合物,但是组合物的精确形状通常取决于给药方式。
通常以掺混物的形式制备组合物,且该组合物适用于口服、胃肠外或局部给药,且因此可以呈片剂、胶囊剂、口服液体制剂、粉剂、颗粒剂、锭剂(lozenges)、锭剂(pastilles)、可重构的粉末、可注射和可灌输的溶液或悬浮液、栓剂和经皮制剂。口服给药的组合物是优选的,特别是成形的口服组合物,因为它们更适用于通常用途。
口服给药的片剂和胶囊剂通常以单剂存在,且含有常规的赋形剂如粘结剂、填料、稀释剂、成片剂(tabletting agents)、润滑剂、崩解剂(disintegrants)、着色剂、调味剂和润湿剂。可以根据本领域公知的方法对片剂进行包衣。
使用的合适填料包括纤维素、甘露醇、乳糖和其它类似的试剂。合适的崩解剂包括淀粉、聚乙烯基吡咯烷酮和淀粉衍生物如淀粉乙醇酸钠。合适的润滑剂包括例如硬脂酸镁。合适的可药用的润湿剂包括月桂基硫酸钠。
可以通过共混、填充、成片等的常规方法制备固体口服组合物。可以使用重复的共混操作来将活性试剂分布在那些使用大量填料的整个组合物中。这类操作当然是本领域中常用的。
口服液体制剂可以呈例如水性或油性悬浮液、溶液、乳液、糖浆或酊剂(elixirs)形式,或者可以作为在使用前用水或其它合适的载体重构的干产品的形式存在。这类液体制剂可以包含常规添加剂如悬浮剂如山梨醇、糖浆、甲基纤维素、明胶、羟乙基纤维素、羧甲基纤维素、硬脂酸铝凝胶或氢化的可食用脂肪、乳化剂如卵磷脂、脱水山梨醇单油酸酯或阿拉伯树胶;非水性载体(可包括可食用的油),例如,杏仁油、分馏的椰子油、油性酯如甘油、丙二醇或乙醇的酯;防腐剂如对羟基苯甲酸甲酯或丙酯或山梨酸,以及需要的常规调味剂或着色剂。
对于胃肠外给药来说,制备包含本发明的化合物和消毒的载体的流体单位剂型。取决于载体和浓度,化合物可以悬浮或溶解。胃肠外溶液通常是通过将活性化合物溶解在载体中,并在填充到合适的小瓶或安瓿中之前过滤消毒,并密封而制备。有利的是,将佐剂如局部麻醉剂、防腐剂和缓冲剂也溶解在载体中。为了增强稳定性,可以在填充到小瓶中后将组合物冷冻并在真空下除去水。
以基本上相同的方式制备胃肠外悬浮液,不同之处在于将活性化合物悬浮在载体中而不是在悬浮在消毒载体中之前溶解并通过暴露于环氧乙烷而消毒。有利的是,将表面活性剂或润湿剂包含在组合物中以方便活性化合物的均匀分布。
通常的实践是,组合物上通常伴随有用于相关的医学治疗的书面或印刷指导。
本发明还提供了治疗和/或预防人类或非人类哺乳动物中的糖尿病、与糖尿病相关的疾病及其某些特定的并发症的方法,包括向需要治疗的人类或非人类哺乳动物给药有效、非毒性量的钠盐或其溶剂化物。
合适的是,活性组分可以作为前面定义的药物组合物的形式给药,且这构成了本发明的一个具体的方面。
在另一个方面,本发明提供了钠盐在生产治疗和/或预防糖尿病、与糖尿病相关的疾病及其某些特定的并发症的药物中的应用。
在治疗和/或预防糖尿病、与糖尿病相关的疾病及其某些特定的并发症中,钠盐或其溶剂化物可以以提供合适剂量的化合物(I)的量摄入,如EP0,306,228,WO 94/05659或WO 98/55122中所披露的量。
本发明的单剂组合物包含钠盐或其可药用的溶剂化物,其量为提供多至12mg,包括1-12mg如2-12mg的化合物(I),尤其是2-4mg,4-8mg或8-12mg的化合物(I),例如1,2,3,4,5,6,7,8,9,10,11或12mg的化合物(I)。因此,具体是,提供了包含钠盐或其可药用的溶剂化物及其可药用的载体的药物组合物,其中钠盐或其可药用的溶剂化物的存在量为提供1,2,4,8,12,4~8或8~12mg的化合物(I),如1mg的化合物(I),如2mg的化合物(I);如4mg的化合物(I);如8mg的化合物(I);如12mg的化合物(I)。
本发明还提供了包含钠盐或其溶剂化物联合使用一种或多种其它抗糖尿病药以及任选的可药用的载体的药物组合物。
本发明还提供了治疗和/或预防人类或非人类哺乳动物中的糖尿病、与糖尿病相关的疾病及其某些特定的并发症的方法,包括给药有效、非毒性量钠盐或其可药用的盐以及一种或多种其它抗糖尿病药。
在另一个方面,本发明提供了钠盐或其可药用的溶剂化物联合使用一种或多种其它抗糖尿病药在生产治疗和/或预防糖尿病、与糖尿病相关的疾病及其某些特定的并发症的药物中的应用。
在前面提到的治疗中,给药钠盐或其可药用的溶剂化物和其它抗糖尿病药包括同时给药或顺序给药活性试剂。
合适的是,在前面提到的组合物(包括单剂)或治疗中,钠盐或可药用的溶剂化物的存在量为提供多至12mg,包括1-12mg,如2-12mg的化合物(I),尤其是2-4mg,4-8mg或8-12mg的化合物(I),例如1,2,3,4,5,6,7,8,9,10,11或12mg的化合物(I)或4-8或8-12mg的化合物(I)。因此,例如,在前面提到的组合物包括单剂,或治疗中,钠盐或可药用的溶剂化物的存在量为提供1mg的化合物(I);钠盐或可药用的溶剂化物的存在量为提供2mg的化合物(I);钠盐或可药用的溶剂化物的存在量为提供3mg的化合物(I);钠盐或可药用的溶剂化物的存在量为提供4mg的化合物(I);钠盐或可药用的溶剂化物的存在量为提供8mg的化合物(I)。
其它抗糖尿病药合适地选自双胍(biguanides)、磺脲(sulphonylureas)和α-葡糖苷酶抑制剂。其它抗糖尿病药优选是双胍。其它抗糖尿病药优选是磺脲。其它抗糖尿病药优选是α-葡糖苷酶抑制剂。合适的抗糖尿病药披露在WO 98/57649、WO 98/57634、WO 98/57635、WO 98/57636、WO 99/03477和WO 99/03476中。将前面提到的公开文件的内容引入本发明中作为参考。
在前面提到的治疗中,本发明的化合物没有显示出不利的毒副作用。
下列实施例用于说明本发明,但决不限制本发明。
实施例
实施例1 5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4二酮,钠盐
在50℃下,将氢氧化钠(0.40g)在水(5ml)中的溶液加入5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮(3.0g)在四氢呋喃(THF,30ml)中的搅拌溶液中。在约1小时内将透明的溶液冷却到21℃并在减压下蒸发掉溶剂以得到作为结晶固体的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮,钠盐(3.2g)。
实施例2 5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4二酮,钠盐
将5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮(3.0g)在丙-2-醇(30ml)中的搅拌悬浮液加热到60℃,然后加入氢氧化钠(0.40g)在水(5ml)中的溶液。将搅拌的混合物加热至回流,得到透明溶液,然后在约1小时内冷却到21℃。通过过滤收集固体沉淀物,用丙-2-醇(10ml)洗涤并在50℃在真空下干燥2小时,得到作为白色结晶固体的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮,钠盐(2.09g)。
实测值:C:56.82,H:4.73,N:10.95;预期值:C:56.97,H:4.78,N:11.08。
1H-NMR(d6-DMSO):与5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮,钠盐一致。
实施例3 5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4二酮,钠盐
将氢氧化钠(3.36g)在水(10ml)中的溶液加入回流下的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4二酮(25.0g)在丙-2-醇(250ml)的搅拌悬浮液中。将搅拌的混合物保持在回流下15分钟,然后在约1小时内冷却到21℃。通过过滤收集固体沉淀物,用丙-2-醇(2x50ml)洗涤并在五氧化二磷上在真空下干燥16小时,得到作为白色结晶固体的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮,钠盐(24.83g)。
实施例2的产物记录的表征数据
使用Nicolet 710 FT-IR分光计在2cm-1分辨率下得到产物的矿物油分散液的红外吸收光谱(图1)。以1cm-1间隔将数据数字化。在1664,1595,1566,1547,1504,1462,1423,1325,1271,1238,1198,1179,1152,1059,1008,977,928,816,784,765,741,729,721,556,520cm-1处观察到谱带。
使用配置有通用的ATR附件的Perkin-Elmer Spectrum One FT-IR分光计记录固体产物的红外光谱。在3059,3032,3010,2940,2872,1663,1593,1560,1546,1502,1463,1422,1369,1323,1270,1227,1198,1179,1152,1112,1059,1008,977,958,926,889,837,816,783,764,741,729,720,691,681cm-1处观察到谱带。
使用Nicolet 960 E.S.P.FT-Raman分光计,在4cm-1分辨率下由功率输出为400mW的Nd:V04激光(1064nm)激发而记录NMR管中的样品的拉曼光谱(图2)。在3060,3011,2942,2914,2872,1686,1674,1608,1595,1583,1558,1464,1450,1433,1425,1413,1387,1317,1276,1232,1210,1180,1097,1054,1009,979,924,890,848,831,785,749,682,642,625,521,484,403,338cm-1处观察到谱带。
使用下列获取条件来记录产品的X-射线粉末衍射图案(图3):阳极管:Cu,发电机电压:40kV,发电机电流:40mA,起始角度:2.0°2θ,最终角度:35.0°2θ,步长:0.02°2θ,每步时间:2.5秒。表征性的XRPD角度和相对强度记录在表1中。
表1
角度 | 相对角度 |
2θ° | % |
3.3 | 50.7 |
6.6 | 22.8 |
9.9 | 100 |
12.2 | 0.6 |
15.3 | 4.5 |
16.5 | 22.9 |
16.9 | 11.8 |
17.3 | 8.1 |
18.4 | 16.9 |
18.8 | 9.3 |
19.9 | 67.5 |
20.4 | 4.7 |
20.9 | 5.7 |
21.0 | 5.9 |
22.0 | 2.2 |
23.0 | 37.6 |
24.1 | 5.7 |
25.1 | 6.4 |
25.7 | 22.2 |
26.5 | 3.9 |
27.4 | 6.6 |
28.5 | 5.5 |
29.4 | 4.2 |
30.0 | 18.6 |
30.7 | 13.6 |
31.4 | 7 |
31.6 | 5.6 |
33.0 | 33.9 |
34.3 | 6.9 |
在90.55MHz下运行的Bruker AMX360仪器上记录钠盐的固态NMR波谱(图4):将固体包装在装有Kel-F帽的4mm氧化锆MAS转子中,且转子在约10kHz下旋转。通过Hartmann-Hahn匹配的质子的交叉极化(cross-polarisation)(CP接触时间3ms,反复时间15s)获取13C MAS光谱,且在获取期间通过使用两脉冲相调制(TPPM)的复合顺序将质子去耦。将化学位移与相对于四甲基硅烷(TMS)的176.4ppm处的甘油的羧酸酯信号外部对照,在37.2,41.4,51.1,62.7,68.9,102.9,109.8,112.1,119.2,130.7,132.1,132.9,138.5,148.9,159.5,191.6,197.7ppm处观察到化学位移。
钠盐的性质
实施例3的产品钠盐的熔点
根据U.S.Pharmacopoeia,USP 23,1995,<741>“Melting range ortemperature,Procedure for Class Ia”,使用Buchi 545熔点仪器所述的方法测定钠盐的熔点。
观察到样品在200℃以上褪色。在230℃形成棕色固体。
棕色固体的熔点:246℃。
实施例2的产品钠盐的T起始
使用Perkin-Elmer DSC7仪器通过差示扫描量热法测定药物的T起始。
T起始(10℃/分钟,封闭盘(closed pan)):155℃,249℃。
Claims (14)
1.化合物5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮钠盐,或其可药用的溶剂化物,其特征在于钠盐是非吸湿的或略微吸湿的。
2.根据权利要求1的化合物,其特征在于它提供下列一种或多种特征:
(i)基本上与图1一致的红外光谱;
(ii)基本上与图2一致的拉曼光谱;
(iii)基本上与表1或图3一致的X-射线粉末衍射图谱(XRPD);
(iv)基本上与图4一致的固态13C NMR波谱;和
(v)熔点范围为245~250℃。
3.根据权利要求1或2的化合物,呈固态剂型。
4.根据权利要求1-3中任一项的化合物,呈松散的研磨的形状。
5.药物组合物,包含权利要求1的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮钠盐(钠盐),或其可药用的溶剂化物,以及其可药用的载体,其中钠盐的存在量为提供多至12mg的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的量。
6.根据权利要求5的药物组合物,包含钠盐或其可药用的盐,其量为提供1,2,4,8或12mg的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的量。
7.根据权利要求5的药物组合物,包含钠盐或其可药用的盐,其量为提供2mg的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的量。
8.根据权利要求5的药物组合物,包含钠盐或其可药用的盐,其量为提供4mg的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的量。
9.根据权利要求5的药物组合物,其量为提供8mg的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的量。
10.药物组合物,包含5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮钠盐或其可药用的盐以及一种或多种其它抗糖尿病药和任选的其可药用的载体,其中钠盐的存在量为提供多至12mg的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的量。
11.治疗和/或预防人类或非人类哺乳动物中的糖尿病、与糖尿病相关的疾病及其某些特定的并发症的方法,包括向需要治疗的人类或非人类哺乳动物给药有效的、非毒性量的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮钠盐或其可药用的盐,其中钠盐的存在量为提供多至12mg的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的量。
12.治疗和/或预防人类或非人类哺乳动物中的糖尿病、与糖尿病相关的疾病及其某些特定的并发症的方法,包括给药有效的、非毒性量的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮钠盐或其可药用的盐以及一种或多种其它抗糖尿病药。
13.用作活性治疗物质的化合物5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮钠盐或其可药用的盐,其中钠盐的存在量为提供多至12mg的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的量。
14.5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮钠盐或其可药用的溶剂化物在生产治疗和/或预防糖尿病、与糖尿病相关的疾病及其某些特定的并发症的药物中的应用,其中钠盐的存在量为提供多至12mg的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的量。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0023971.5 | 2000-09-29 | ||
GBGB0023971.5A GB0023971D0 (en) | 2000-09-29 | 2000-09-29 | Novel pharmaceutical |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018165621A Division CN100345846C (zh) | 2000-09-29 | 2001-09-28 | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101125852A true CN101125852A (zh) | 2008-02-20 |
Family
ID=9900428
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA200710148814XA Pending CN101125853A (zh) | 2000-09-29 | 2001-09-28 | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 |
CNB018165621A Expired - Fee Related CN100345846C (zh) | 2000-09-29 | 2001-09-28 | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 |
CN2006101091200A Expired - Fee Related CN1915992B (zh) | 2000-09-29 | 2001-09-28 | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 |
CNA2007101488135A Pending CN101125852A (zh) | 2000-09-29 | 2001-09-28 | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA200710148814XA Pending CN101125853A (zh) | 2000-09-29 | 2001-09-28 | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 |
CNB018165621A Expired - Fee Related CN100345846C (zh) | 2000-09-29 | 2001-09-28 | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 |
CN2006101091200A Expired - Fee Related CN1915992B (zh) | 2000-09-29 | 2001-09-28 | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 |
Country Status (27)
Country | Link |
---|---|
US (4) | US20040014752A1 (zh) |
EP (2) | EP1813612A1 (zh) |
JP (1) | JP2004509959A (zh) |
KR (1) | KR100917953B1 (zh) |
CN (4) | CN101125853A (zh) |
AP (1) | AP1738A (zh) |
AU (2) | AU9202801A (zh) |
BG (1) | BG107679A (zh) |
BR (1) | BR0114308A (zh) |
CA (1) | CA2423975A1 (zh) |
CZ (1) | CZ302181B6 (zh) |
DZ (1) | DZ3480A1 (zh) |
EA (1) | EA005109B1 (zh) |
EC (1) | ECSP034528A (zh) |
GB (1) | GB0023971D0 (zh) |
HU (1) | HUP0301188A3 (zh) |
IL (2) | IL155051A0 (zh) |
MA (1) | MA25912A1 (zh) |
MX (1) | MXPA03002868A (zh) |
NO (2) | NO20031435L (zh) |
NZ (1) | NZ524933A (zh) |
OA (1) | OA12399A (zh) |
PL (1) | PL363701A1 (zh) |
SK (1) | SK3782003A3 (zh) |
UA (1) | UA74842C2 (zh) |
WO (1) | WO2002026735A1 (zh) |
ZA (1) | ZA200302439B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8133637B2 (en) * | 2005-10-06 | 2012-03-13 | Headwaters Technology Innovation, Llc | Fuel cells and fuel cell catalysts incorporating a nanoring support |
US7435741B2 (en) * | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
WO2011075514A1 (en) * | 2009-12-15 | 2011-06-23 | Metabolic Solutions Development Company | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0306228B1 (en) * | 1987-09-04 | 1999-11-17 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
GB9124513D0 (en) * | 1991-11-19 | 1992-01-08 | Smithkline Beecham Plc | Novel process |
GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
GB9308487D0 (en) * | 1993-04-23 | 1993-06-09 | Smithkline Beecham Plc | Novel compounds |
GB9723295D0 (en) * | 1997-11-04 | 1998-01-07 | Smithkline Beecham Plc | Novel process |
CN1253236A (zh) * | 1998-11-11 | 2000-05-17 | 李扬远 | 一种以重力差释放引力能的方法 |
CN1183130C (zh) * | 1999-09-24 | 2005-01-05 | 中国人民解放军军事医学科学院毒物药物研究所 | 噻唑烷类衍生物及其医药用途 |
HU225919B1 (en) * | 1999-12-18 | 2007-12-28 | Richter Gedeon Nyrt | Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates |
GB0006133D0 (en) * | 2000-03-14 | 2000-05-03 | Smithkline Beecham Plc | Novel pharmaceutical |
-
2000
- 2000-09-29 GB GBGB0023971.5A patent/GB0023971D0/en not_active Ceased
-
2001
- 2001-09-28 CZ CZ20030850A patent/CZ302181B6/cs not_active IP Right Cessation
- 2001-09-28 KR KR1020037004497A patent/KR100917953B1/ko not_active IP Right Cessation
- 2001-09-28 SK SK378-2003A patent/SK3782003A3/sk unknown
- 2001-09-28 PL PL01363701A patent/PL363701A1/xx not_active Application Discontinuation
- 2001-09-28 EA EA200300422A patent/EA005109B1/ru not_active IP Right Cessation
- 2001-09-28 MX MXPA03002868A patent/MXPA03002868A/es unknown
- 2001-09-28 CN CNA200710148814XA patent/CN101125853A/zh active Pending
- 2001-09-28 NZ NZ524933A patent/NZ524933A/xx unknown
- 2001-09-28 OA OA1200300090A patent/OA12399A/en unknown
- 2001-09-28 HU HU0301188A patent/HUP0301188A3/hu unknown
- 2001-09-28 IL IL15505101A patent/IL155051A0/xx unknown
- 2001-09-28 AP APAP/P/2003/002767A patent/AP1738A/en active
- 2001-09-28 JP JP2002531119A patent/JP2004509959A/ja active Pending
- 2001-09-28 DZ DZ013480A patent/DZ3480A1/fr active
- 2001-09-28 US US10/381,496 patent/US20040014752A1/en not_active Abandoned
- 2001-09-28 AU AU9202801A patent/AU9202801A/xx active Pending
- 2001-09-28 CN CNB018165621A patent/CN100345846C/zh not_active Expired - Fee Related
- 2001-09-28 EP EP07107325A patent/EP1813612A1/en not_active Withdrawn
- 2001-09-28 CA CA002423975A patent/CA2423975A1/en not_active Abandoned
- 2001-09-28 WO PCT/GB2001/004334 patent/WO2002026735A1/en active Application Filing
- 2001-09-28 AU AU2001292028A patent/AU2001292028B2/en not_active Ceased
- 2001-09-28 UA UA2003032737A patent/UA74842C2/uk unknown
- 2001-09-28 CN CN2006101091200A patent/CN1915992B/zh not_active Expired - Fee Related
- 2001-09-28 EP EP01972248A patent/EP1332142A1/en not_active Withdrawn
- 2001-09-28 CN CNA2007101488135A patent/CN101125852A/zh active Pending
- 2001-09-28 BR BR0114308-5A patent/BR0114308A/pt not_active Application Discontinuation
-
2003
- 2003-03-26 BG BG107679A patent/BG107679A/bg unknown
- 2003-03-28 NO NO20031435A patent/NO20031435L/no unknown
- 2003-03-28 MA MA27076A patent/MA25912A1/fr unknown
- 2003-03-28 ZA ZA200302439A patent/ZA200302439B/en unknown
- 2003-03-28 EC EC2003004528A patent/ECSP034528A/es unknown
-
2004
- 2004-05-18 US US10/849,603 patent/US20050277679A9/en not_active Abandoned
-
2005
- 2005-08-17 US US11/205,424 patent/US20060004058A1/en not_active Abandoned
-
2007
- 2007-04-23 US US11/738,586 patent/US20070185167A1/en not_active Abandoned
- 2007-12-13 IL IL188116A patent/IL188116A0/en unknown
- 2007-12-18 NO NO20076517A patent/NO20076517L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK286399B6 (sk) | V podstate nehydratovaná a nehygroskopická alebo iba mierne hygroskopická hydrochloridová soľ 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie | |
CN1915992B (zh) | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 | |
CN100558717C (zh) | 新型医药 | |
CN1620453B (zh) | 噻唑烷二酮衍生物及其作为抗糖尿病药的用途 | |
CN1458931A (zh) | 噻唑烷二酮衍生物的酒石酸盐 | |
CN100415741C (zh) | 一种噻唑烷二酮衍生物以及其制备抗糖尿病药的应用 | |
EP1305311B1 (en) | Tartrate salt of thiazolidinedione derivative | |
CN100390170C (zh) | 5-(4-(2-(n-甲基-n-(2-吡啶基)氨基)乙氧基)苄基)噻唑烷-2,4-二酮苯磺酸盐,它的制备方法,其多晶型物ⅰ、ⅱ和ⅲ和它作为药物活性成分的用途 | |
CN1458930A (zh) | 噻唑烷二酮衍生物的酒石酸盐 | |
AU2001292028A1 (en) | Sodium salts of 5-'4-'2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione | |
CN101712678A (zh) | 四氢噻唑二酮衍生物的酒石酸盐 | |
DE102005027274A1 (de) | Inhibitoren der löslichen Adenylatzyklase | |
WO2003050114A1 (en) | Sulfate salt of a thiazolidinedione derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080220 |